

DAFTAR PUSTAKA

1. Cornelissen C, Hobbs M. Lippincott's Illustrated Reviews: Microbiology. 4th Edition. Pennsylvania: Lippincott Williams & Wilkins; 2020.
2. Kementerian Kesehatan Republik Indonesia. Laporan Nasional Riskesdas 2018. Jakarta: Lembaga Penerbit Balitbangkes; 2018.
3. Hanlon G, Hodges N. Essential Microbiology for Pharmacy and Pharmaceutical Science. Chichester: John Wiley & Sons, Ltd; 2013.
4. Kementerian Kesehatan Republik Indonesia. Pedoman Umum Penggunaan Antibiotik. Jakarta: Kementerian Kesehatan RI; 2013.
5. Indijah S, Fajri P. Modul Bahan Ajar Cetak Farmasi: Farmakologi. Jakarta: Kementerian Kesehatan RI; 2016.
6. Klein E, Boeckel T, Martinez E, Pant S, Gandra S, Levin S. Global Increase and Geographic Convergence in Antibiotic Consumption Between 2000 and 2015. 2018;115(15):3463–70. doi: 10.1073/pnas.1717295115.
7. Arrang S, Cokro F, Sianipar E. Penggunaan Antibiotika yang Rasional pada Masyarakat Awam di Jakarta. J Mitra. 2019;3(1):73–82.
8. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2021 Tentang Pedoman Penggunaan Antibiotik. Jakarta: Menteri Kesehatan Republik Indonesia; 2021.
9. Saputri R, Hakim A. Profil Penggunaan Antibiotika di Puskesmas Hantakan dan Profil Dagusibu Antibiotika di Desa Hantakan dan Desa Alat. J Pharm Care Sci. 2021;1(2):126–31. doi: 10.33859/jpcs.v2i1.71.
10. Mahardika E, Maharani L, Suryoputri M. Analisis Kualitatif Faktor-Faktor Pendukung Kepatuhan Pasien Infeksi dalam Menggunakan Antibiotik Sefksim Setelah Masa Rawat Inap di Rumah Sakit Prof. Dr. Margono Soekarjo. Acta Pharm Indones. 2018;6(2):66. doi: 10.20884/1.api.2018.6.2.1243.
11. Murray C, Ikuta K, Sharara F, Swetschinski L, Aguilar G, Gray A, et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet. 2022;399(10325):629–55. doi: 10.1016/S0140-6736(21)02724-0.
12. Porooshat D. Antimicrobial Resistance : Implications and Costs. Infect Drug Resist. 2019;12(1):3903–10. doi: 10.2147/IDR.S234610.
13. Dewi R, Meirista I, Husna R. Kajian Pola Peresepan Antibiotik pada Pasien Dewasa di Puskesmas Rawat Inap Nipah Panjang Kabupaten Tanjung Jabung Timur Tahun 2019. J Sains dan Kesehat. 2022;4(3):256–61. doi: 10.25026/jsk.v4i3.1019.
14. Ramlah S, Nur D, Hanifa C. Rasionalitas Penggunaan Antibiotik Pada Pasien Rawat Jalan di Puskesmas Loa Janan Tahun 2020. Borneo Stud Res. 2021;3(1):1002–10.
15. Indriani L, Zunnita O. Penilaian Terhadap Rasionalitas Penggunaan Antibiotika pada Balita Penderita Pneumonia Puskesmas Bogor Utara. 2018;08(2):92–9. doi: 10.33751/jf.v8i2.1572.
16. Finch R, Norrby R, Whitley R, editors. Antibiotic and Chemotherapy: Anti Infective Agents and Their Use In Therapy. 9th editio. Birmingham: Elsevier Health Sciences; 2010.
17. Ebimiewei E, Ibemologi A. Antibiotics: Classification and Mechanisms of Action with Emphasis on Molecular Perspectives. Int J Appl Microbiol

- Biotechnol Res. 2016;4(September 2017):90–101.
18. Li D, Zhou B, Bei L. Antibacterial Therapeutic Agents Composed of Functional Biological Molecules. 2020;2020. doi: 10.1155/2020/6578579.
 19. Southwick F. Infectious Diseases: A Clinical Short Course. 4th Editio. McGraw Hill LLC; 2020.
 20. Kurnianta P, Sari S, Yanti S, Alfianna W, Solihah R, Okzelia S, et al. Pengantar Farmakologi: Konsep dan Teori. PT. Sonpedia Publishing Indonesia; 2023.
 21. Goering R, Dockrell HM, Zuckerman M, Chiodini P, Wahid M, Kusumaningrum A, et al. Mims' Medical Microbiology. 6 edition. Amsterdam: Elsevier Health Sciences; 2021.
 22. Gualerzi C, Brandi L, Fabbretti A, Pon C, editors. Antibiotics : Target, Mechanism and Resistance. Weinheim: Wiley-VCH; 2014.
 23. Black A, Ray S. Antiprotozoal drugs. Side Eff Drugs Annu. 14th editi. 2019;41:293–300. doi: 10.1016/bs.seda.2019.07.006.
 24. Center for Biotechnology Information. Compound Summary for CID 5959, Chloramphenicol [Internet]. PubChem. 2024 [cited 2024 Jul 26]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Chloramphenicol#section=Structures>.
 25. Irianto I. Senyawa Alam sebagai Antibakteri dan Mekanisme Aksinya. UGM Press; 2022.
 26. Center for Biotechnology Information. Compound Summary for CID 14969, Vancomycin [Internet]. PubChem. 2024 [cited 2024 Jul 26]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Vancomycin#section=Structures>
 27. Gallagher J, Macdougall C. Antibiotics Simplified. 5th editio. Massachusetts: Jones & Bartlett Learning; 2022.
 28. Ihsan S. Analisis Rasionalitas Antibiotik Di Fasilitas Pelayanan Kesehatan. Deepublish; 2021.
 29. Trevor A, Katzung B, Kruidering-Hall M. Pharmacology Examination & Board Review. 12th editi. San Fransisco: McGraw-Hill Education; 2019.
 30. Gladwin M, Trattler W, Mahan C. Clinical Microbiology Made Ridiculously Simple. 6th editio. Miami: MedMaster, Inc; 2014.
 31. Wax R, Lewis K, Salyers A, Taber H, editors. Bacterial Resistance to Antimicrobials. 2nd editio. Bacterial Resistance to Antimicrobials. New York: CRC Press; 2008.
 32. Chisholm-Burns M, Schwinghammer T, Malone P, Kolesar J, Bookstaver B, editors. Pharmacotherapy Principles & Practice. 6th editio. New York: McGraw Hill; 2022.
 33. Parthasarathy A. Textbook of Pediatric Infectious Diseases. New Delhi: Jaypee Brothers Medical Publishers Pvt. Ltd; 2013.
 34. Muntasir, Abdulkadir W, Harun A, Mulyadi, Saksosno R, Fernandez S. Antibiotik dan Resistensi Antibiotik. Rizmedia Pustaka Indonesia; 2022.
 35. Setyarini A, Indriani R, Munandar D, Faizah N, Megasari A, Mildawati R, et al. Farmakologi Dasar. Get Press; 2022.
 36. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406 Tahun 2011 Tentang Pedoman Umum Penggunaan Antibiotik. Menteri Kesehat Republik Indoonesia.

- 2011;19(6):34–44.
37. Byrne M, Miellet S, Mcglinn A, Fish J, Meedya S, Reynolds N, et al. The drivers of Antibiotic Use and Misuse : The Development and Investigation of a Theory Driven Community Measure. 2019;1–11. doi: 10.1186/s12889-019-7796-8.
 38. Limato R, Lazarus G, Dernison P, Mudia M, Alamanda M, Nelwan E, et al. Articles Optimizing Antibiotic Use in Indonesia : A Systematic Review and Evidence Synthesis to Inform Opportunities for Intervention. *Lancet Reg Heal*. 2022;2(6). doi: 10.1016/j.lansea.2022.05.002.
 39. AHFS. AHFS Drug Information, American Society of Health System Pharmacists. Bethesda: American Hospital Formulary Service; 2015.
 40. Sweetman S. The 36th Edition of Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press; 2009.
 41. Medscape Drug and Disease. cefadroxil (Rx) [Internet]. [cited 2024 Mar 16]. Available from: <https://reference.medscape.com/drug/duricef-ultracef-cefadroxil-342489#4>
 42. Stuhan M. Understanding Pharmacology for Pharmacy Technicians. 2nd editio. Maryland: American Society of Health-system Pharmacists; 2023.
 43. Whalen K. Illustrated Reviews: Pharmacology. South Asia. Sharma S, Velpandian T, editors. New Delhi: Wolters Kluwer Health; 2019.
 44. Kokkarachedu V, Kanikireddy V, Sadiku R, editors. Antibiotic Materials in Healthcare. London: Elsevier Inc; 2020.
 45. Medscape Drug and Disease. Cefixime (Rx) [Internet]. [cited 2024 Mar 16]. Available from: <https://reference.medscape.com/drug/suprax-cefixime-342503#4>
 46. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 9 Tahun 2017 Tentang Apotek. Menteri Kesehatan Republik Indonesia; 2017.
 47. Setyani W, Putri D. Resep Dan Peracikan Obat. Sanata Dharma University Press; 2020.
 48. Romdhoni M. Kaidah Penulisan Resep Obat. Karita D, Maulana AM, editors. Yogyakarta: Deepublish; 2020.
 49. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 73 Tahun 2016 Tentang Standar Pelayanan Kefarmasian di Apotek. Menteri Kesehatan Republik Indonesia; 2016.
 50. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan RI Nomor 74 Tahun 2016 Tentang Standar Pelayanan Kefarmasian di Puskesmas. Jakarta: Menteri Kesehatan Republik Indonesia; 2016.
 51. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 75 Tahun 2014. Jakarta: Menteri Kesehatan Republik Indonesia; 2014.
 52. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nmomor HK.01.07/Menkes/2015/2023 Tentang Petunjuk Teknis Integrasi Pelayanan Kesehatan Primer. Jakarta: Menteri Kesehatan Republik Indonesia; 2023.
 53. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 30 Tahun 2014 Tentang Standar Pelayanan Kefarmasian di Puskesmas. Jakarta: Menteri Kesehatan Republik Indonesia;

- 2014.
54. Ferizal. Sejarah Lahirnya Puskesmas, ASN, BKN, Kementerian PANRB, KORPRI, KUA Dan Akreditasi Puskesmas. Sukabumi: Jejak Publisher; 2022.
 55. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Nomor 5 tahun 2014 Tentang Panduan Praktik Klinis bagi Dokter di Fasilitas Pelayanan Kesehatan Primer. Indonesia: Menteri Kesehatan Republik Indonesia; 2014.
 56. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. *Circulation*. 2015;132(15):1435–86. doi: 10.1161/CIR.0000000000000296.
 56. Grant J, Le Saux N. Duration of Antibiotic Therapy for Common Infections. *J Assoc Med Microbiol Infect Dis Canada*. 2021;6(3):181–97. doi: 10.3138/JAMMI-2021-04-29.
 57. Barlam T, Cosgrove S, Abbo L, Macdougall C, Schuetz A, Septimus E, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis*. 2016;62(10):e51–77. doi: 10.1093/cid/ciw118.
 58. Dellit T. Summary of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. *Infect Dis Clin Pract*. 2007;15(4):263–4. doi: 10.1097/IPC.0b013e318068b1c0.
 59. The Lancet Infectious Diseases. Antibiotic resistance: Long-term solutions require action now. *Lancet Infect Dis*. 2013;13(12):995. doi: 10.1016/S1473-3099(13)70290-1.
 60. Brunton L, Knollmann B, Hilal-Dandan R. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 13 edition. New York: McGraw Hill Medical; 2018.
 61. Kliegman R, Stanton B, Geme J, Schor N. Nelson Textbook of Pediatrics. 20 edition. Amsterdam: Elsevier Health Sciences; 2015.
 62. Mangoni A, Jackson S. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. *Br J Clin Pharmacol*. 2004;57(1):6–14. doi: 10.1046/j.1365-2125.2003.02007.x.
 63. Dawson-Hahn E, Mickan S, Onakpoya I, Roberts N, Kronman M, Butler C, et al. Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: A review of systematic reviews. *Fam Pract*. 2017;34(5):511–9. doi: 10.1093/fampra/cmz037.
 64. Shu Y, Zhang Q, He X, Liu Y, Wu P, Chen L. Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database. *Front Pharmacol*. 2022;13(September):1–10. doi: 10.3389/fphar.2022.990241.
 65. Johanesen P, Mackin K, Hutton M, Awad M, Larcombe S, Amy J, et al. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. *Genes (Basel)*. 2015;6(4):1347–60. doi: 10.3390/genes6041347.

66. Davies J. Origins and Evolution of Antibiotic Resistance. *Microbiología*. 2010;12(1):9–16. doi: 10.1128/mmbr.00016-10.
67. Pailhoriès H, Herrmann J, Velo-Suarez L, Lamoureux C, Beauruelle C, Burgel P, et al. Antibiotic Resistance in Chronic Respiratory Diseases: From Susceptibility Testing to the Resistome. *Eur Respir Rev*. 2022;31(164). doi: 10.1183/16000617.0259-2021.
68. Ventola L. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. *Pharm Ther*. 2015;40(4):277–83. doi: 10.1016/B978-1-4831-9711-1.50022-3.
69. Bradley J, Byington C, Shah S, Alverson B, Carter E, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. *Clin Infect Dis*. 2011;53(7):25–76. doi: 10.1093/cid/cir531.
70. Smith R, Coast J. The Economic Burden of Antimicrobial Resistance: Why it is More Serious than Current Studies Suggest. *London Sch Hyg Trop Med*. 2012;44(0):1–34.
71. Spellberg B, Bartlett J, Gilbert D. The Future of Antibiotics and Resistance. *N Engl J Med*. 2013;368(4):299–302. doi: 10.1056/NEJMp1215093.
72. Arulkumaran N, Routledge M, Schlebusch S, Lipman J, Morris A. Antimicrobial Associated Harm in Critical Care: A Narrative Review. *Intensive Care Med*. 2020;46(2):225–35. doi: 10.1007/s00134-020-05929-3.
73. Llor C, Bjerrum L. Antimicrobial resistance: Risk Associated with Antibiotic Overuse and Initiatives to Reduce the Problem. *Ther Adv Drug Saf*. 2014;5(6):229–41. doi: 10.1177/2042098614554919.

